Ginkgo Bioworks (DNA) announced its partnership with Carnegie-Mellon University for an award by the Advanced Research Projects Agency for Health for its POSEIDON program. With Ginkgo Bioworks serving as the Commercial Partner, the project will also be led by Rebecca Taylor, professor of mechanical engineering at Carnegie Mellon University. As part of this team, Ginkgo plans to apply its cell and enzyme engineering expertise to support development of these new diagnostic tools. In addition to Carnegie Mellon researchers, the multidisciplinary project team includes academic experts from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, as well as corporate partners at Ginkgo Bioworks, Velentium Medical, Clinical Research Strategies, and Platypus Bio.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks, Agricen enter collaboration
- Ginkgo Bioworks partners with Deep Origin to develop new drug safety tools
- Ginkgo Bioworks awarded four-year, up to $47M contract from EMSL
- Private Markets: Prediction market platform Kalshi secures $300M
- Private Markets: Anthropic to invest $50B in computing infrastructure